Biologically active insulin derivatives
The problem of insufficient stability and affinity of existing insulin analogs is solved by introducing additional covalent linkages between the insulin A and B chains, and its biological activity and therapeutic properties are improved.
CN118909079AInactive Publication Date: 2024-11-08CHEM & BIOPHARML LAB OF PATRAS
Patent Information
- Application Number
- CN202410996682.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2013-12-05
- Filing Date
- 2014-12-04
- Publication Date
- 2024-11-08
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Technical Problem
Existing insulin analogs are blocked when binding to insulin receptors, resulting in reduced affinity and insufficient stability and solubility, affecting the therapeutic effect.
Method used
By introducing additional covalent linkages between the insulin A and B chains, additional bonds are formed using amino acid side chain functional groups, reducing chain flexibility and improving chemical stability while retaining bonds between chains to alleviate receptor binding resistance. The problem.
Benefits of technology
Improves the chemical stability and enzyme stability of insulin analogues, enhances its biological activity and therapeutic properties, and improves its affinity with insulin receptors.
✦ Generated by Eureka AI based on patent content.
Smart Images

Figure BDA0004960429640000011 
Figure BDA0004960429640000012 
Figure BDA0004960429640000081
Abstract
The present invention relates to insulin derivatives having biological activity. One aspect of the invention relates to single-chain insulin analogs comprising: (A) a chain A of human or animal insulin, or an analog or derivative thereof; (B) a B chain of human or animal insulin, or an analog or derivative thereof; (C) one or more disulfide bonds between the A chain and the B chain; and (D) another covalent linkage L between the functional group of the amino acid of the A chain and the functional group of the amino acid of the B chain, at least one of said functional groups being an amino acid side chain functional group. Another aspect of the invention relates to pharmaceutical compositions comprising said single-chain insulin derivatives, and therapeutic uses thereof.
Need to check novelty before this filing date? Find Prior Art
Citation Information
Patent Citations
Single-chain insulin
CN102816228A
Single chain insulin agonists exhibiting high activity at the insulin receptor
CN103068842A
Single-chain insulin
CN1902226A
Process for the preparation of insulin derivatives cross-linked by a dicarboxylic acid group at the amino a-1 glycine and amino b-29 lysine
US3847893A
Ester insulin
WO2011031662A1
